» Articles » PMID: 38371808

Diterpenoid Tanshinones Can Inhibit Lung Cancer Progression by Improving the Tumor Microenvironment and Downregulation of NF-κB Expression

Overview
Journal ACS Omega
Specialty Chemistry
Date 2024 Feb 19
PMID 38371808
Authors
Affiliations
Soon will be listed here.
Abstract

Diterpenoid tanshinones (DTs) are a bioactive fraction extracted from . High-performance liquid chromatography analysis revealed the presence of four compounds, namely, tanshinone IIA, tanshinone I, cryptotanshinone, and dihydrotanshinone. In this study, we aimed to propose a possible mechanism for the anti-lung cancer effect of DT. To do so, we utilized a lung cancer nude mice model and a lung cancer cell line (PC9) to investigate the effect of DT on lung cancer. We employed immunohistochemistry, enzyme-linked immunosorbent assay, hematoxylin and eosin staining, and immunofluorescence to analyze the pharmacological role of DT in the inhibition of lung cancer growth. The results showed that DT inhibited tumor growth, induced apoptosis in the nude mice model, and reduced inflammatory cell infiltration. Additionally, DT inhibited PC9 lung cancer cells, growth, proliferation, and migration. The mechanism of action of DT involves not only directly inhibiting cell proliferation and migration but also improving the tumor microenvironment. DT significantly increased the expression of important intestinal gap junction proteins, such as zonula occludens 1 (ZO-1) and occludin I. This upregulation contributes to the reinforcement of the intestinal mucosal barrier, thereby reducing the paracellular transport of lipopolysaccharides (LPS) through the intestine. Consequently, the decreased LPS levels lead to the inhibition of NF-κB expression and downregulation of macrophage polarization, as indicated by the decreased expression of CD68. In conclusion, this study has confirmed that DT has anti-lung cancer properties by improving the inflammatory tumor microenvironment via regulating macrophage polarization and inhibiting LPS-associated immune response. These results provide new insights into the mechanism of DT action against lung cancer.

References
1.
Nasrollahzadeh E, Razi S, Keshavarz-Fathi M, Mazzone M, Rezaei N . Pro-tumorigenic functions of macrophages at the primary, invasive and metastatic tumor site. Cancer Immunol Immunother. 2020; 69(9):1673-1697. PMC: 11027658. DOI: 10.1007/s00262-020-02616-6. View

2.
Zhang X, Su C, Zhao S, Li J, Yu F . Combination therapy of Ulinastatin with Thrombomodulin alleviates endotoxin (LPS) - induced liver and kidney injury via inhibiting apoptosis, oxidative stress and HMGB1/TLR4/NF-κB pathway. Bioengineered. 2022; 13(2):2951-2970. PMC: 8973693. DOI: 10.1080/21655979.2021.2024686. View

3.
Li Z, Zhang Y, Zhou Y, Wang F, Yin C, Ding L . Tanshinone IIA suppresses the progression of lung adenocarcinoma through regulating CCNA2-CDK2 complex and AURKA/PLK1 pathway. Sci Rep. 2021; 11(1):23681. PMC: 8654884. DOI: 10.1038/s41598-021-03166-2. View

4.
Shi M, Huang F, Deng C, Wang Y, Kai G . Bioactivities, biosynthesis and biotechnological production of phenolic acids in Salvia miltiorrhiza. Crit Rev Food Sci Nutr. 2018; 59(6):953-964. DOI: 10.1080/10408398.2018.1474170. View

5.
Wang Y, Ji R, Chen W, Huang S, Zheng Y, Yang Z . Paclitaxel alleviated sepsis-induced acute lung injury by activating MUC1 and suppressing TLR-4/NF-κB pathway. Drug Des Devel Ther. 2019; 13:3391-3404. PMC: 6766586. DOI: 10.2147/DDDT.S222296. View